Patent · US Active

Substituted nucleoside analogues for use as PRMT5 inhibitors

US10898504B2 · kind B2 · utility

0Cited by

1References

17Claims

0Family size

Assignee

Janssen Pharmaceuticals, Inc. · BE

Inventors

Didier Jean-Claude Berthelot · Edegem, BE
Dirk Brehmer · Glückstadt, DE
Lijs Beke · Ekeren, BE
An Boeckx · Herentals, BE
Gaston Stanislas Marcella Diels · Turnhout, BE
Ronaldus Arnodus Hendrika Joseph Gilissen · Beerse, BE
Edward C. Lawson · Pipersville, US
Vineet Pande · Vosselaar, BE
Marcus Cornelis Bernardus Catharina Paradé · Eindhoven, NL
Wim Bert Griet Schepens · Sint-Katelijne-Waver, BE
Brian C. Shook · Holliston, US
Johannes Wilhelmus John F. Thuring · Ekeren, BE
Marcel Viellevoye · Breda, NL
Weimei Sun · North Wales, US
Tongfei Wu · Leuven, BE
Lieven Meerpoel · Beerse, BE

Key dates

Filing date	Feb 24, 2017
Grant date	Jan 26, 2021
Priority date	—
Expiry date	Oct 30, 2037

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K31/7064
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates novel substituted nucleoside analogues of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as PRMT5 inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.